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Introduction
Schnitzler syndrome (SchS) was first described in 1972
and to date 281 cases have been reported. SchS is an
adult onset, apparently acquired disease, which clinically
closely resembles CAPS including the response to IL-1
blockade. A hallmark of the disease is the IgM kappa
paraprotein, identified in 85% of the patients; recently
variant IgG have been reported in 7% of cases.
Objective
To characterise clinical symptoms in the 13 patients
with SchS identified at the single UK centre. Recently,
mosaicism in the NLRP3 gene was described in two
cases with SchS, which prompted us to search for
mosaic variants in our cohort.
Methods
13 patients underwent detailed clinical investigations and
analysis of the NLRP3 and NLRP12 genes by Sanger and
multiparallel sequencing (MPS). In addition MYD88 gene
was sequenced in the DNA extracted from whole blood.
Results
The median age at disease onset was 55 years (range 35-
78). All patients presented with uricarial rash, other
manifestations included fever (77%), arthralgia (69%),
weight loss (46%), fatigue (38%), bone pain (38%) and
lymphadenopathy (23%). One patient was diagnosed
with AA amyloidosis. In all subjects low grade IgM
kappa paraprotein had been detected.
Genetic testing revealed two patients had V198M
and F402L variants in the NLRP3 and NLRP12 genes
respectively. No additional nucleotide alternations,
including somatic mosaicism, in the NLRP3 exons: 3, 4
and 6 have been identified by MPS. In addition no
mutation was found in MYD88 gene by PCR/Sanger
sequencing.
Conclusion
Despite of the recent report of NLRP3 somatic mosaicism
in two cases, in the current study, except for the two var-
iants of unknown significance: V198M and F402L identi-
fied in the NLRP3 and NLRP12 genes respectively, no
other genetic alternation was found by either Sanger or
MPL sequencing in the 13 cases with SchS. We failed to
identify variation in the MYD88 gene, looking specifically
for the L265P variant, which is a known risk factor for the
development of Waldenstorm macroglobulinemia. The
limitation of this study is that the analysis was performed
on the DNA isolated from peripheral blood rather than
the bone marrow (BM) and we plan to repeat this experi-
ment on the BM samples.
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